---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020257"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:05:04.431183+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics COO Lawrence Klein resigns; search for successor underway

## Summary
- COO Lawrence Klein, Ph.D., resigns effective Oct 27, 2022; will stay through year-end for transition.
- CEO Samarth Kulkarni thanked Klein for seven years of contributions to strategy and leadership.
- Company is conducting a search to find a successor for the COO role.
- Klein cited exa-cel poised for regulatory filing and five other clinical programs as company strengths.

## SEC filing metadata
- accession: 0000950170-22-020257
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020257/0000950170-22-020257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020257/crsp-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020257
- JSON: https://secwatch.observer/filing/0000950170-22-020257.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020257.txt

## Key facts
- Executive change
  Lawrence O. Klein resigned as Chief Operating Officer at CRISPR Therapeutics AG.
  - Action: resigned
  - Role: Chief Operating Officer
  source text: On October 27, 2022, Lawrence O. Klein, Ph.D. resigned from his position as Chief Operating Officer of CRISPR Therapeutics AG.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020257/0000950170-22-020257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.